FLT3 and acute myeloid leukemia: The use of midostaurin in CBF AML is currently being explored in a phase II study (NCT03686345), and a trial of midostaurin in c-KIT or FLT3-ITD mutated t(8,21) AML recently completed accrual (NCT01830361).